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IntramuscularThe pharmacokinetics of dexamethasone (DEX) were investigated after an intravenous (IV) or intramus-
cular (IM) bolus injection of 0.3 mg/kg bodyweight DEX sodium phosphate in pigs. The plasma
concentrations of DEX were determined using a validated high-performance liquid chromatography–
tandem mass spectrometry (LC–MS/MS) method and the pharmacokinetics were determined by
one-compartmental analysis.
The mean area under the plasma concentration–time curve and the mean elimination half-life were
133.07 ± 39.59 ng.h/mL and 0.77 h, and 173.24 ± 53.59 ng h/mL and 1.06 h following IV and IM adminis-
tration, respectively. The volume of distribution and clearance recorded after IV administration were
2.78 ± 0.88 L/kg and 2.39 ± 0.57 L/h kg, respectively.
An IM bolus injection of DEX sodium phosphate in pigs resulted in a fast and complete absorption, with
a mean maximal plasma concentration of 80.94 ± 21.29 ng/mL at 0.35 ± 0.21 h and a high absolute
bioavailability of 131.06 ± 26.05%.
 2013 Elsevier Ltd. All rights reserved.Dexamethasone (DEX) is a long-acting synthetic hydrocortisone
analogue and is one of the most potent glucocorticoid drugs. It is
extensively used in veterinary medicine to treat inflammatory,
immunological and allergic disorders (Toutain et al., 1982; EMA,
2004; Ferguson et al., 2009). In livestock, the use of DEX is indi-
cated in inflammatory processes such as mastitis, aseptic laminitis,
arthritis and primary ketosis. DEX is also reported to be used as an
illegal growth promoter (Courtheyn et al., 2002; Ferguson et al.,
2009; Vincenti et al., 2009).
In order to improve water solubility, glucocorticoids are often
formulated as a phosphate ester prodrug, which rapidly hydrolyses
and releases free and active alcohols (Rohdewald et al., 1987; EMA,
2004). The pharmacokinetic (PK) properties of DEX have been pre-
viously described in humans and diverse animal species, but not in
pigs although it has been approved for treatment of inflammatory
and allergic disorders in this species (EMA, 2004).
The aim of this study was to determine the PK properties of DEX
in pigs. The results will be applied in ongoing research studying the
immunomodulatory properties of DEX, either alone or in combina-
tion with several antibiotics in a porcine lipopolysaccharide (LPS)
inflammation model (Wyns et al., 2013).
The experiment was approved by the Ethical Committee of the
Faculty of Veterinary Medicine of Ghent University (EC 2011/156).Six clinically healthy male pigs (Landrace) with a mean body-
weight (BW) of 28.3 ± 3.01 kg were randomly divided in two
groups. The animals had free access to feed and drinking water.
The experiment was performed as a two-way cross-over design
with a wash-out period of 5 days. A bolus of 0.3 mg/kg BW DEX so-
dium phosphate (DEXA 0.2%, Kela Laboratoria) was injected intra-
venously (IV) in the ear vein or intramuscularly (IM) in the gluteus
muscle via a sterile winged infusion needle (25 G; Micro-flo, Novo-
lab). Blood was collected by venepuncture of the jugular vein into
EDTA-coated tubes (Vacutest Kima) before administration (time
0 h) and at 0.08, 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, 10, 12 and 24 h post-
administration (p.a.). Blood samples were centrifuged at 2800 g
for 10 min at 4 C and plasma was stored at 615 C until analysis
within 2 months.
Quantification of DEX in porcine plasma was performed using a
validated liquid chromatography–tandem mass spectrometry
(LC–MS/MS) method, which was previously described in detail by
our department (Watteyn et al., 2013). The PK properties were
determined by means of WinNonlin, version 6.2.0 software pro-
gram (Pharsight Corporation) using a one-compartmental model.
Values below the limit of quantification of 2 ng/mL were not
included in the analysis.
The mean area under the plasma concentration–time curve
(AUC0?1) was calculated using the linear trapezoidal method with
extrapolation to infinity. The absolute bioavailability (F) was
calculated from the following equation:gs. The
Table 1
Pharmacokinetic parameters (mean ± SD) of dexamethasone (DEX) in pigs after
intravenous (IV) and intramuscular (IM) bolus injection of 0.3 mg/kg BW DEX sodium
phosphate (n = 6).
Parameter Units IV IM
AUC0?1 h ng/mL 133.07 ± 39.59 173.24 ± 53.59
kabs /h – 12.90 ± 10.57
kel /h 0.90 ± 0.28 0.65 ± 0.30
t1/2abs h – 0.05a
t1/2el h 0.77a 1.06a
Vd L/kg 2.78 ± 0.88 –
Cl L/h kg 2.39 ± 0.57 –
tmax h – 0.35 ± 0.21
C0 ng/mL 114.89 ± 26.56 –
Cmax ng/mL – 80.94 ± 21.29
F % – 131.06 ± 26.05
AUC, area under the curve; kabs, absorption rate constant; kel, elimination rate
constant; t1/2abs, half-life of absorption; t1/2el, half-life of elimination; Vd, volume of
distribution; Cl, clearance; tmax, time to maximum plasma concentration; C0,
maximum plasma concentration at 0 h; Cmax, maximum plasma concentration; F,
absolute bioavailability.
a Harmonic mean.
2 H. Wyns et al. / The Veterinary Journal xxx (2013) xxx–xxxFð%Þ ¼ AUC0!1IM
AUC0!1IV
 100
Data are presented as means ± standard deviation (SD) and
were statistically analysed by single-factor analysis of variance
(ANOVA), using SPSS Version 20.0 software for Windows. The level
of significance was a = 0.05.
No adverse effects following IV or IM administration were ob-
served during the course of the study. Semi-logarithmic plots of
the mean plasma concentration–time curves following IV and IM
administration are presented in Fig. 1. Quantifiable concentrations
of DEX were measured in plasma until 4 h after both IV and IM
administration. The PK properties of DEX (mean ± SD) are summa-
rised in Table 1.
Following an IV bolus injection of 0.3 mg/kg BW DEX sodium
phosphate, the AUC0?1 was 133.07 ± 39.59 ng h/mL. The elimina-
tion half-life (t1/2el) was 0.77 h and the volume of distribution (Vd)
and clearance (Cl) were 2.78 ± 0.88 L/kg and 2.39 ± 0.57 L/h kg,
respectively. Following an IM bolus injection of 0.3 mg/kg BW
DEX sodium phosphate, the AUC0?1 was 173.24 ± 53.59 ng h/mL.
A maximal plasma concentration (Cmax) of 80.94 ± 21.29 ng/mL
was reached at 0.35 ± 0.21 h (tmax). The t1/2el was 1.06 h and the
absolute bioavailability of DEX after IM injection was
131.06 ± 26.05%. None of the PK properties significantly differed
between both administration routes.
The present study is the first to describe the pharmacokinetics
and bioavailability of DEX after IV and IM administration in pigs.
DEX was supplied as a water-soluble and stable sodium phosphate
ester to pigs and, as previously established by Rohdewald et al.
(1987), DEX sodium phosphate is rapidly converted to the free
and active alcohol form of DEX. Therefore, DEX alcohol, and not
the esterified prodrug, was currently measured in plasma using
the previously validated LC–MS/MS method.
An IM bolus injection of 0.3 mg/kg BW DEX sodium phosphate
in pigs resulted in a relatively fast absorption and a Cmax of DEX
at 0.35 h (tmax). However, in horses a faster tmax of 0.16 h was
recently observed (Soma et al., 2013). After an IM injection, DEX
sodium phosphate is fully bioavailable in pigs (F = 131%), horses
(F = 100%; Soma et al., 2013) and broiler chickens (F = 123%; Wat-
teyn et al., 2013). In dogs, an IM administration of DEX alcohol
resulted in a relatively early Cmax at 0.63 h and a complete absorp-
tion, while in cattle a delayed Cmax at 4.27 h and an absolute bio-
availability of only 67% was observed. Likewise, after an IM bolus
injection of DEX 21-isonicotinate, an early Cmax at 0.50 h and a de-Fig. 1. Mean (±SD) plasma concentration–time profiles of dexamethasone (DEX) after
Quantifiable concentrations of DEX were measured in plasma for 4 h after IV and IM ad
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However, the absolute bioavailability was barely 40% in dogs com-
pared to 72% in cattle (Toutain et al., 1982, 1983).
In comparison with other mammalian species, a remarkably
high clearance of DEX was observed in pigs (2.39 L/h kg). Con-
versely, in dogs, cattle, horses and humans, a clearance of <0.6 L/
h kg was reported (Toutain et al., 1982, 1983; Rohdewald et al.,
1987; Greco et al., 1993; Hochhaus et al., 2001; Soma et al.,
2013). In most species, the Vd of DEX is <2 L/kg (Toutain et al.,
1982, 1983; Hochhaus et al., 2001; Soma et al., 2013). Interestingly,
the Vd of DEX in pigs was 2.78 L/kg, which suggests good tissue
penetration. However, a relatively short t1/2el (0.77 h) was observed
in pigs. In other species, DEX is considered to be a long-acting
(>48 h) glucocorticoid in comparison to hydrocortisone and pred-
nisolone. Notwithstanding the PK results observed in this study,
DEX could have a longer action in pigs from the pharmacodynamic
perspective.
In conclusion, an IM bolus injection of DEX sodium phosphate
in pigs resulted in fast and complete absorption, followed by a fast
elimination of the active DEX alcohol. The Vd and particularly the
clearance of DEX are much higher in pigs compared with other
mammalian species.IV and IM bolus injection of 0.3 mg/kg BW DEX sodium phosphate in pigs (n = 6).
ministration (LOQ = 2 ng/mL).
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